moneyheap
SRPT · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Sarepta Therapeutics, Inc. Common Stock (SRPT) stock moving?
Sarepta reported a Q3 2026 beat on Nov 5, with adjusted EPS of $0.13 versus a $0.06 estimate and sales reported at $381.4M versus $353.0M expected. Net product revenue was $323.8M, including $240.3M from PMO and $83.5M from ELEVIDYS. Non-GAAP operating income was $22.9M, GAAP operating loss was $9.0M, and management described positive cash flow. The company raised the low end of its 2026 net product revenue guidance by $50M and lowered the high end of its expense guidance by $25M. Two analysts raised targets to $18 (RBC, and Deutsche Bank with a Hold upgrade from Sell). Despite this, the stock closed at $16.42 on Nov 10, down from $17.82 on Nov 6 and about 15% below the $19.32 close on Oct 28. Volume on Nov 10 was 3.36M, roughly double the prior 10-day average near 1.6M, which points to heavy selling. The Nov 9 pre-market decline followed the reappointment of Vinay Prasad as the FDA's top vaccine official, a development with unclear direct relevance to Sarepta. Upcoming multiple ascending dose data for SRP-1003 (DM1) and SRP-1001 (FSHD) are expected in Q4 2026, and the company is preparing Phase 3 work. The ELEVIDYS liver safety profile remains a risk factor that the company says it is addressing.
News behind the analysis
- Deutsche Bank Upgrades Sarepta Therapeutics to HoldDeutsche Bank upgraded Sarepta from Sell to Hold and raised its price target from $14 to $18.
- Sarepta Therapeutics Shares Decline Following FDA Personnel ChangeSarepta shares fell in pre-market trading after Vinay Prasad was reappointed as the FDA's top vaccine official.
- RBC Raises Price Target on Sarepta TherapeuticsRBC Capital Markets raised its price target on Sarepta after the third-quarter earnings release.
- RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Raises Price Target to $18RBC kept its Sector Perform rating and lifted its price target to $18 following the quarterly report.
- Sarepta Therapeutics Q3 2026 Earnings Call TranscriptSarepta reported third-quarter 2026 results on Nov 5; the earnings call transcript was published.
- Sarepta Therapeutics Reports Third Quarter 2026 Financial ResultsQ3 net product revenue was about $323.8M ($240.3M PMO, $83.5M ELEVIDYS); the 2026 revenue guidance low end was raised $50M and the expense high end lowered $25M. MAD data for DM1 and FSHD is expected in Q4 2026.
- Sarepta Therapeutics Q3 Adj. EPS $0.13 Beats $0.06 Estimate, Sales $381.400M Beat $352.961M EstimateSarepta beat consensus on adjusted EPS and sales for the third quarter of 2026.
- Sarepta Therapeutics SVP Wendy Erler Joins Astrosalva Therapeutics Strategic Advisory BoardSarepta SVP of Patient Affairs Wendy Erler was appointed to the advisory board of preclinical biotech Astrosalva Therapeutics.
About Sarepta Therapeutics,, Inc. Common Stock
Sarepta Therapeutics is a Cambridge, Massachusetts biotech that makes RNA-based and gene therapies for rare diseases, mainly Duchenne muscular dystrophy (DMD), a muscle-wasting disease. It is known for ELEVIDYS, one of the few approved DMD gene therapies, whose sales slowed after safety concerns; Michael Severino became CEO in July 2026.
How it makes money
Most revenue comes from selling its DMD drugs in the US. These are three exon-skipping drugs (EXONDYS 51, VYONDYS 53 and AMONDYS 45), which brought in roughly 70% of product sales in the first half of 2026, plus the gene therapy ELEVIDYS at about 30%. Roche sells ELEVIDYS outside the US and pays Sarepta milestones and royalties under a partnership deal. The company has guided to about $1.2–1.4 billion in total 2026 revenue.
What usually moves SRPT
- ELEVIDYS demand and safety news
- FDA regulatory decisions and label changes
- Clinical trial readouts (DM1, FSHD, Duchenne)
- Competition in Duchenne treatments
- Quarterly sales versus guidance